Related references
Note: Only part of the references are listed.Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
C. Hiemke et al.
PHARMACOPSYCHIATRY (2018)
Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers
Carmen Belmonte et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Is CYP2D6 phenotype predictable from CYP2D6 genotype?
Adam Ferenc Kiss et al.
MICROCHEMICAL JOURNAL (2018)
Classics in Chemical Neuroscience: Aripiprazole
Austen B. Casey et al.
ACS CHEMICAL NEUROSCIENCE (2017)
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol
A. Parabiaghi et al.
ACTA PSYCHIATRICA SCANDINAVICA (2016)
Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol
Patteet Lisbeth et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro
Yun-Yun Zhan et al.
XENOBIOTICA (2016)
Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics
Edoardo Spina et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype
Katalin Toth et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
CYP450 genotype and pharmacogenetic association studies: a critical appraisal
Rashmi R. Shah et al.
PHARMACOGENOMICS (2016)
Phenoconversion and therapeutic drug monitoring
Jose de Leon
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients
Katalin Monostory et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Addressing phenoconversion: the Achilles' heel of personalized medicine
Rashmi R. Shah et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
Jennifer E. Thomas et al.
CURRENT NEUROPHARMACOLOGY (2015)
The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients
Karen van der Weide et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2015)
Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey
Gudrun Hefner et al.
JOURNAL OF NEURAL TRANSMISSION (2015)
Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta- analysis of randomized controlled trials
Taro Kishi et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2015)
Effects of Genetic Polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
Takeshi Suzuki et al.
THERAPEUTIC DRUG MONITORING (2014)
The CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes
Maho Okubo et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2013)
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Laure Elens et al.
PHARMACOGENOMICS (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Complexities of CYP2D6 gene analysis and interpretation
Andrea Gaedigk
INTERNATIONAL REVIEW OF PSYCHIATRY (2013)
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
Junichi Azuma et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and Expression
Manna Temesvari et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
Marianne Ulcickas Yood et al.
BMC PSYCHIATRY (2011)
Pharmacokinetics and metabolism update for some recent antipsychotics
Silvio Caccia
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Aripiprazole and Dehydroaripiprazole Plasma Concentrations and Clinical Responses in Patients With Schizophrenia
Shih-Ku Lin et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Update Information on Drug Metabolism Systems-2009, Part II. Summary of Information on the Effects of Diseases and Environmental Factors on Human Cytochrome P450 (CYP) Enzymes and Transporters
Slobodan Rendic et al.
CURRENT DRUG METABOLISM (2010)
A Systematic Review of Aripiprazole-Dose, Plasma Concentration, Receptor Occupancy, and Response: Implications for Therapeutic Drug Monitoring
Anna Sparshatt et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part II
Shu-Feng Zhou
CLINICAL PHARMACOKINETICS (2009)
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part I
Shu-Feng Zhou
CLINICAL PHARMACOKINETICS (2009)
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Shu-Feng Zhou et al.
DRUG METABOLISM REVIEWS (2009)
Influence of Comedication on Serum Concentrations of Aripiprazole and Dehydroaripiprazole
Ragnhild Birkeland Waade et al.
THERAPEUTIC DRUG MONITORING (2009)
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia:: An [18F]fallypride PET study
Gerhard Gruender et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Ulrich M. Zanger et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2008)
Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug
Jonathan N. Bauman et al.
DRUG METABOLISM AND DISPOSITION (2008)
Large intraindividual variability of olanzapine serum concentrations in adolescent patients
Christian J. Bachmann et al.
THERAPEUTIC DRUG MONITORING (2008)
Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects
Katrin M. Kirschbaum et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2008)
Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole
Magnhild Hendset et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia:: A triple tracer PET study
David Mamo et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients
Espen Molden et al.
THERAPEUTIC DRUG MONITORING (2006)
Cytochrome P450 (CYP) inhibition screening: Comparison of three tests
Miia Turpeinen et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions
RS Obach et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes
T Yamamoto et al.
XENOBIOTICA (2003)
Increased transcriptional activity of the CYP3A4* 1B promoter variant
B Amirimani et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2003)
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity
E Garcia-Martin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test
CB Eap et al.
THERAPEUTIC DRUG MONITORING (2001)
Managing antipsychotic-induced acute and chronic akathisia
CH Miller et al.
DRUG SAFETY (2000)
Share Paper
